American Journal of Ophthalmology
Volume 146, Issue 6 , Pages 828-836 , December 2008

Ocular Inflammation in Behçet Disease: Incidence of Ocular Complications and of Loss of Visual Acuity

  • R. Oktay Kaçmaz

      Affiliations

    • Massachusetts Eye Research and Surgery Institution, Cambridge, Massachusetts
    • ,
  • John H. Kempen

      Affiliations

    • Ocular Inflammation Service, Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania
    • Center for Preventive Ophthalmology and Biostatistics, Department of Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania
    • Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, the University of Pennsylvania, Philadelphia, Pennsylvania
    • ,
  • Craig Newcomb

      Affiliations

    • Ocular Inflammation Service, Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania
    • Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, the University of Pennsylvania, Philadelphia, Pennsylvania
    • ,
  • Sapna Gangaputra

      Affiliations

    • Department of Ophthalmology, the Johns Hopkins University, Baltimore, Maryland
    • ,
  • Ebenezer Daniel

      Affiliations

    • Department of Ophthalmology, the Johns Hopkins University, Baltimore, Maryland
    • ,
  • Grace A. Levy-Clarke

      Affiliations

    • Laboratory of Immunology, National Eye Institute, Bethesda, Maryland
    • ,
  • Robert B. Nussenblatt

      Affiliations

    • Laboratory of Immunology, National Eye Institute, Bethesda, Maryland
    • ,
  • James T. Rosenbaum

      Affiliations

    • Department of Ophthalmology, Oregon Health and Science University, Portland, Oregon
    • Department of Medicine, Oregon Health and Science University, Portland, Oregon
    • ,
  • Eric B. Suhler

      Affiliations

    • Department of Ophthalmology, Oregon Health and Science University, Portland, Oregon
    • Portland Veteran's Affairs Medical Center, Portland, Oregon
    • ,
  • Jennifer E. Thorne

      Affiliations

    • Department of Ophthalmology, the Johns Hopkins University, Baltimore, Maryland
    • Department of Epidemiology, the Johns Hopkins University, Baltimore, Maryland
    • ,
  • Douglas A. Jabs

      Affiliations

    • Department of Ophthalmology, the Johns Hopkins University, Baltimore, Maryland
    • ,
  • C. Stephen Foster

      Affiliations

    • Massachusetts Eye Research and Surgery Institution, Cambridge, Massachusetts
    • Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts
    • Corresponding Author InformationInquiries to C. Stephen Foster, Massachusetts Eye Research and Surgery Institution, 5 Cambridge Center, 8th Floor, Cambridge, MA 21042
    • ,
  • Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study Group

,Accepted 17 June 2008.

References 

  1. Behçet H. Uber rezidivierende Aphtose, durch ein Virus verursachte Geschwure am Mund, am Auge und an den Genitalien. Dermatol Wochenschr. 1937;105:1152–1157
  2. Foster CS. Diagnosis and Treatment of Uveitis. In: Philadelphia, Pennsylvania: WB Saunders; 2001;p. 632–652
  3. International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet. 1990;335:1078–1080
  4. Verity DH, Wallace GR, Vaughan RW, Stanford MR. Behçet's disease: from Hippocrates to the third millennium. Br J Ophthalmol. 2003;87:1175–1183
  5. Evereklioglu C. Current concepts in the etiology and treatment of Behçet disease. Surv Ophthalmol. 2005;50:297–350
  6. Kempen JH, Daniel E, Gangaputra S, et al. Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study Research Group Methods for identifying long-term adverse effects of treatment in patients with eye diseases: The Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study. Ophthalmic Epidemiol. 2008;15:47–55
  7. Jabs DA, Nussenblatt RB, Rosenbaum JT, et al. Standardization of uveitis nomenclature for reporting clinical data (Results of the First International Workshop). Am J Ophthalmol. 2005;140:509–516
  8. Kempen JH, Jabs DA, Wilson LA, Dunn JP, West SK, Tonascia JA. Risk of vision loss in patients with cytomegalovirus retinitis and the acquired immunodeficiency syndrome. Arch Ophthalmol. 2003;121:466–476
  9. Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. J Am Stat Association. 1989;84:1074–1078
  10. Mamo JG. The rate of visual loss in Behçet's disease. Arch Ophthalmol. 1970;84:451–452
  11. Boyd SR, Young S, Lightman S. Immunopathology of the noninfectious posterior and intermediate uveitides. Surv Ophthalmol. 2001;46:209–233
  12. Michelson JB, Chisari FV. Behçet's disease. Surv Ophthalmol. 1982;26:190–203
  13. Muhaya M, Lightman S, Ikeda E, et al. Behçet's disease in Japan and in Great Britain: a comparative study. Ocul Immunol Inflamm. 2000;8:141–148
  14. Kitaichi N, Miyazaki A, Iwata D, Ohno S, Stanford MR, Chams H. Ocular features of Behçet's disease: an international collaborative study. Br J Ophthalmol. 2007;91:1579–1582
  15. Yoshida A, Kawashima H, Motoyama Y, et al. Comparison of patients with Behçet's disease in the 1980s and 1990s. Ophthalmology. 2004;111:810–815
  16. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M. Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol. 2004;138:373–380
  17. Keino H, Okada AA. Behçet's disease: global epidemiology of an Old Silk Road disease. Br J Ophthalmol. 2007;91:1573–1574
  18. Krause I, Yankevich A, Fraser A, et al. Prevalence and clinical aspects of Behçet's disease in the North of Israel. Clin Rheumatol. 2007;26:555–560
  19. Salvarani C, Pipitone N, Catanoso MG, et al. Epidemiology and clinical course of Behçet's disease in the Reggio Emilia area of Northern Italy: a seventeen-year population-based study. Arthritis Rheum. 2007;57:171–178
  20. Sakamoto M, Akazawa K, Nishioka Y, Sanui H, Inomata H, Nose Y. Prognostic factors of vision in patients with Behçet disease. Ophthalmology. 1995;102:317–321
  21. Takeuchi M, Hokama H, Tsukahara R, et al. Risk and prognostic factors of poor visual outcome in Behçet's disease with ocular involvement. Graefes Arch Clin Exp Ophthalmol. 2005;243:1147–1152
  22. Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behçet's syndrome. N Engl J Med. 1990;322:281–285
  23. Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease. Lancet. 1989;1:1093–1096
  24. Durrani K, Ahmed M, Foster CS. Adamantiades-Behçet disease: diagnosis and current concepts in management of ocular manifestations. Compr Ophthalmol Update. 2007;8:225–233
  25. Accorinti M, Pirraglia MP, Paroli MP, Priori R, Conti F, Pivetti-Pezzi P. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease. Jpn J Ophthalmol. 2007;51:191–196
  26. Takamoto M, Kaburaki T, Numaga J, Fujino Y, Kawashima H. Long-term infliximab treatment for Behçet's disease. Jpn J Ophthalmol. 2007;51:239–240
  27. Kotter I, Gunaydin I, Zierhut M, Stubiger N. The use of interferon alpha in Behçet disease: review of the literature. Semin Arthritis Rheum. 2004;33:320–335
  28. Demiroglu H, Barista I, Dundar S. Risk factor assessment and prognosis of eye involvement in Behçet's disease in Turkey. Ophthalmology. 1997;104:701–705

PII: S0002-9394(08)00485-6

doi: 10.1016/j.ajo.2008.06.019

American Journal of Ophthalmology
Volume 146, Issue 6 , Pages 828-836 , December 2008

Article Tools

* Image Usage & Resolution